{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:57:47Z","timestamp":1785571067841,"version":"3.56.0"},"reference-count":37,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100012151","name":"sanming project of medicine in shenzen municipality","doi-asserted-by":"publisher","award":["SZSM202211012"],"award-info":[{"award-number":["SZSM202211012"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"national cancer center","doi-asserted-by":"publisher","award":["E010324028"],"award-info":[{"award-number":["E010324028"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dalpiciclib is the latest cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor approved in China. Real-world data regarding the efficacy and safety of dalpiciclib for metastatic breast cancer (MBC) are still insufficient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aims to investigate the real-world outcomes of dalpiciclib in a more heterogeneous population of patients with MBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>We retrospectively collected data of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+\/HER2\u2212) MBC patients who received dalpiciclib plus endocrine therapy (ET) between January 2022 to March 2025 from four clinical centers in South China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Demographic characteristics and clinical data were collected. Real-world progression-free survival (rwPFS), objective response rate (ORR), and safety profiles were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 160 patients were included. The median follow-up time was 17.6\u2009months (95% confidence interval (CI): 15.0\u201320.2). The estimated overall median rwPFS was 20.6\u2009months (95% CI: 12.4\u201328.8), and the ORR was 17.5% (28\/160) for the entire cohort. Subgroup analysis showed that the median rwPFS was 26.7\u2009months in patients receiving first-line dalpiciclib plus ET, compared with 13.8\u2009months in those receiving second- or later-line treatment. The median rwPFS for patients with brain metastases (BMs;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200913) was 14.8\u2009months (95% CI: 4.0\u201325.6), and the median rwPFS for patients treated by prior CDK4\/6 inhibitors (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200933) was 7.2\u2009months. Stratified Cox regression analysis revealed that the presence of de novo metastatic disease was an independent factor for an increased risk of disease progression (hazard ratio 0.47, 95% CI: 0.25\u20130.91,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.025). Hematologic toxicity was the most frequent adverse event associated with dalpiciclib treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this real-world cohort of HR+\/HER2\u2212 MBC patients, dalpiciclib plus ET retains its favorable clinical activity. This regimen also showed promising activity in patients with BMs and those previously exposed to CDK4\/6 inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261467382","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:13:22Z","timestamp":1785345202000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dalpiciclib combined with endocrine therapy for patients with HR+\/HER2\u2212 metastatic breast cancer: a multicenter real-world study"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-6340","authenticated-orcid":false,"given":"Xuelian","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital &amp; Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Shenzhen University and Shenzhen Second People\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangning","family":"He","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Dongguan People\u2019s Hospital, Dongguan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital &amp; Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital &amp; Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital &amp; Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital &amp; Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital &amp; Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital &amp; Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiwen","family":"Du","sequence":"additional","affiliation":[{"name":"Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital &amp; Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 113rd Baohe Road, Longgang District, Shenzhen 518100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"e_1_3_4_2_2","volume-title":"Breast cancer facts & figures 2022\u20132024","author":"American Cancer Society","year":"2022","unstructured":"American Cancer Society. Breast cancer facts & figures 2022\u20132024. Atlanta: American Cancer Society, 2022."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19323"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2019.01.006"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21777"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102670"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_3_4_12_2","article-title":"Overall survival (OS) with first-line palbociclib plus letrozole (PAL\u2009+\u2009LET) versus placebo plus letrozole (PBO\u2009+\u2009LET) in women with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer (ER+\/HER2 ABC): analyses from PALOMA-2","volume":"40","author":"Finn RS","year":"2022","unstructured":"Finn RS, Rugo HS, Dieras VC, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL\u2009+\u2009LET) versus placebo plus letrozole (PBO\u2009+\u2009LET) in women with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer (ER+\/HER2 ABC): analyses from PALOMA-2. J Clin Oncol 2022; 40: LBA1003 (paper presented at annual meeting of the American Society of Clinical Oncology, 27\u201331 May 2022, Chicago, IL, USA).","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00172-9"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01562-9"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13957"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1231-7"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105570"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.03.023"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2025.03.003"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241302018"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.062745"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03864-9"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00198-5"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0433"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1764"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02392"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02086"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01940"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01865"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000354253"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2025.10.018"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-82137-9"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35174"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-024-07761-2"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33132"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.06.006"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07226-1"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261467382","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261467382","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261467382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:19:20Z","timestamp":1785568760000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261467382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":37,"alternative-id":["10.1177\/17588359261467382"],"URL":"https:\/\/doi.org\/10.1177\/17588359261467382","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17588359261467382"}}